Drug Development in NMIBC from Scientific, Regulatory, Clinician, and Patient Perspectives (2021)
America/New York GMT -4 summer
Opening Remarks, Recap from Previous Day, and Goal Setting, SESSION TWO: Clinical Dilemmas in Management of NMIBC, Trial Design Considerations for Intermediate Risk NMIBC, The Natural History of High Risk NMIBC: Novel Therapies versus Cystectomy, Sequential Therapy in BCG Unresponsive Disease, Discussion, Q&A, Keynote: The Science of Combination Therapy, Keynote: Racial Disparities in Cancer Clinical Trials, Closing Remarks
Previous registration necessary?
Simultaneous translation ?
Will it be recorded?
Matthew Galsky, Yair Lotan, Trinity Bivalacqua, Angela Smith, Sima Porten, Adam Palmer, Otis Webb Brawley